Reviewing MIRA Pharmaceuticals (MIRA) & Its Competitors

MIRA Pharmaceuticals (NASDAQ:MIRA) is one of 1,004 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare MIRA Pharmaceuticals to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Profitability

This table compares MIRA Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-293.51%	-229.04%
MIRA Pharmaceuticals Competitors	-2,992.57%	-287.70%	-33.64%

Institutional & Insider Ownership

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for MIRA Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	0	0	0	0	N/A
MIRA Pharmaceuticals Competitors	6704	19255	45708	970	2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 74.98%. Given MIRA Pharmaceuticals’ rivals higher probable upside, analysts clearly believe MIRA Pharmaceuticals has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares MIRA Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	-$11.98 million	-0.95
MIRA Pharmaceuticals Competitors	$1.68 billion	$153.43 million	-2.56

MIRA Pharmaceuticals’ rivals have higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

MIRA Pharmaceuticals rivals beat MIRA Pharmaceuticals on 7 of the 9 factors compared.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.